FDA Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency
标准简介
Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency[附网盘链接]是FDA于之前发布的FDA标准,适用于U.S。标准截图
![Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency[附网盘链接]](/img/202109141036273v1p9.jpg)
标准文档说明
标准文档类型为Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency[附网盘链接]高清PDF版本(文字版),标准文档内可进行搜索,可以复制原文,可粘贴。标准部分原文
Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency Guidance for Industry, Investigators, and Institutional Review Boards This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA office responsible for this guidance as listed on the title page. I. Introduction FDA plays a critical role in protecting the United States from threats such as emerging infectious diseases, including the Coronavirus Disease 2019 (COVID-19) pandemic. FDA is committed to providing timely guidance to support response efforts to this pandemic. FDA is issuing this guidance to provide general considerations to assist sponsors in assuring the 1
safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity for the duration of the COVID-19 public health emergency. This document updates the guidance of the same title issued in January 2021 (previous versions December, September, July, June, May, April, and March 2020). The appendix to this guidance further explains those general considerations by providing answers to questions that the Agency has received about conducting clinical trials during the COVID-19 public health emergency. 1
In this document, the terms trial participant or participant are used and are interchangeable with the term subject as used in referenced FDA regulations. 1
网盘链接
百度网盘:https://pan.baidu.com/s/10MZTb66-yrrePPa6X3zOHQ
提取码:72i2
【温馨提示】大资料ISO是提供信息发布的专业信息类网站,所有内容均由用户发布,不代表本站观点,本站亦不存储所涉及的文件及资料。如有【免费资料】以及【付费资料】,请用户根据自己的需求,自行判断是否需要获取。如有交易诈骗、内容侵权可发送邮件至kf@dzl100.com,我们审查后若发现情况属实,会立即对相关内容进行删除处理。
加载用时:232.6934 毫秒
相关评论
相关文章
-
FDA Adaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry
Adaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry[附网盘链接]是FDA于过去发布的FDA标准,适用于美国。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Expansion Cohorts Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics
Expansion Cohorts Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics[附网盘链接]是Food&Drug Administration于过去发布的FDA标准,适用于US。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products
Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products[附网盘链接]是FDA于不久之前发布的FDA标准,适用于美国。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Core Patient-Reported Outcomes in Cancer Clinical Trials Draft Guidance for Industry
Core Patient-Reported Outcomes in Cancer Clinical Trials Draft Guidance for Industry[附网盘链接]是Food&Drug Administration于不久前发布的FDA标准,适用于U.S。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA E17 General Principles for Planning and Design of Multi-Regional Clinical Trials
E17 General Principles for Planning and Design of Multi-Regional Clinical Trials[附网盘链接]是Food&Drug Administration于不久前发布的FDA标准,适用于美国。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Expanded Access to Investigational Drugs for Treatment Use - Questions and Answers
Expanded Access to Investigational Drugs for Treatment Use - Questions and Answers[附网盘链接]是Food&Drug Administration于不久前发布的FDA标准,适用于U.S。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Exculpatory Language in Informed Consent
Exculpatory Language in Informed Consent[附网盘链接]是FDA于不久前发布的FDA标准,适用于美国。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Allowable Excess Volume and Labeled Vial Fill Size in Injectable Drug and Biological Products
Allowable Excess Volume and Labeled Vial Fill Size in Injectable Drug and Biological Products[附网盘链接]是Food And Drug Administration于不久之前发布的FDA标准,适用于US。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Adverse Accreditation Decisions, SuspensionRevocation of Certificates, or Patient and Physician Notification Orders Draft
Adverse Accreditation Decisions, SuspensionRevocation of Certificates, or Patient and Physician Notification Orders Draft[附网盘链接]是Food And Drug Administration于不久之前发布的FDA标准,适用于United States。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
CVM GFI #185 (VICH GL43) Target Animal Safety for Veterinary Pharmaceutical Products.pdf[网盘链接]
GFI #185 (VICH GL43) Target Animal Safety for Veterinary Pharmaceutical Products.pdf是于发布的标准,适用于。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances
Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances[附网盘链接]是FDA于过去发布的FDA标准,适用于美国。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Adaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry
Adaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry[附网盘链接]是FDA于过去发布的FDA标准,适用于美国。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Assay Migration Studies for In Vitro Diagnostic Devices Guidance for Industry and FDA Staff
Assay Migration Studies for In Vitro Diagnostic Devices Guidance for Industry and FDA Staff[附网盘链接]是FDA于过去发布的FDA标准,适用于United States。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Clinical Pharmacology Labeling for Human Prescription Drug and Biological Products — Content and Format
Clinical Pharmacology Labeling for Human Prescription Drug and Biological Products — Content and Format[附网盘链接]是Food And Drug Administration于当前发布的FDA标准,适用于United States。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。
-
FDA Chronic Hepatitis D Virus Infection Developing Drugs for Treatment Guidance for Industry
Chronic Hepatitis D Virus Infection Developing Drugs for Treatment Guidance for Industry[附网盘链接]是Food&Drug Administration于当前发布的FDA标准,适用于United States。本次分享的标准文档为高清PDF(文字版),标准文档内可搜索,可复制,可粘贴。本文结尾附网盘链接。